Valuation: Orgenesis Inc.

Capitalization 98.28L 84.81L 79.09L 73.28L 1.35Cr 85Cr 1.52Cr 9.59Cr 3.61Cr 40Cr 3.69Cr 3.61Cr 145.95Cr P/E ratio 2022
-3.29x
P/E ratio 2023 -0.26x
Enterprise value 3.16Cr 2.73Cr 2.54Cr 2.36Cr 4.35Cr 271.97Cr 4.88Cr 31Cr 12Cr 127.35Cr 12Cr 12Cr 469.46Cr EV / Sales 2022
1.8x
EV / Sales 2023 71.2x
Free-Float
79.55%
Yield 2022 *
-
Yield 2023 -
More valuation ratios * Estimated data
Dynamic Chart
1 day-1.34%
1 week-15.00%
Current month-25.08%
1 month-39.84%
3 months-49.54%
6 months-20.50%
Current year-41.53%
More quotes
1 week 1
Extreme 1
1.3
1 month 1
Extreme 1
1.81
Current year 1
Extreme 1
5.89
1 year 0.87
Extreme 0.87
10.8
3 years 0.87
Extreme 0.87
26.4
5 years 0.87
Extreme 0.87
83
10 years 0.87
Extreme 0.87
168
More quotes
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 71 02/02/2012
Chief Executive Officer 56 24/12/2013
Director of Finance/CFO 55 02/01/2024
Director TitleAgeSince
Chairman 56 14/08/2014
Director/Board Member 54 17/04/2012
Director/Board Member 59 22/02/2017
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-1.34%-15.00%-84.61%-94.88% 73.56L
-8.67%-9.87%+15.03%+12.52% 23TCr
-1.26%-1.01%+8.91%+0.68% 12TCr
-0.77%-0.77%+31.03%+110.13% 5.77TCr
+0.07%+0.54%-23.75%-23.84% 5.11TCr
+0.85%+6.42%-9.93%+43.09% 4.23TCr
+0.98%-0.71%-25.97%+10.21% 3.3TCr
+0.41%-1.35%-11.31%+13.03% 2.44TCr
-0.93%-2.49%-1.63%+8.20% 2.24TCr
-0.75%-6.22%+11.28%-41.08% 2.21TCr
Average -1.16%-2.26%-9.09%+3.81% 5.97TCr
Weighted average by Cap. -3.62%-0.27%+6.21%+16.48%
See all sector performances

Financials

2022 2023
Net sales 3.6Cr 3.11Cr 2.9Cr 2.69Cr 4.95Cr 309.94Cr 5.56Cr 35Cr 13Cr 145.13Cr 14Cr 13Cr 535Cr 5L 5L 4L 4L 7L 4.56Cr 8L 51.7L 19.47L 2.14Cr 19.88L 19.47L 7.87Cr
Net income -1.49Cr -1.28Cr -1.2Cr -1.11Cr -2.05Cr -128.1Cr -2.3Cr -15Cr -5.47Cr -60Cr -5.58Cr -5.47Cr -221.11Cr -5.54Cr -4.78Cr -4.46Cr -4.13Cr -7.61Cr -476.3Cr -8.54Cr -54Cr -20Cr -223.02Cr -21Cr -20Cr -822.16Cr
Net Debt 1.5Cr 1.29Cr 1.2Cr 1.12Cr 2.06Cr 128.72Cr 2.31Cr 15Cr 5.49Cr 60Cr 5.61Cr 5.5Cr 222.18Cr 2.18Cr 1.88Cr 1.75Cr 1.62Cr 2.99Cr 187.42Cr 3.36Cr 21Cr 8Cr 88Cr 8.17Cr 8Cr 323.51Cr
More financial data * Estimated data
Logo Orgenesis Inc.
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.
Employees
146
More about the company
Date Price Change Volume
17/25/17 1.105 $ -1.34% 1,362
16/25/16 1.120 $ -5.88% 11,980
15/25/15 1.190 $ +0.85% 4,844
14/25/14 1.180 $ +10.28% 7,381
11/25/11 1.070 $ -17.69% 16,314

Delayed Quote OTC Markets, July 17, 2025 at 09:03 pm IST

More quotes

Quarterly revenue - Rate of surprise